In the current study, we use a well-characterized model of prostate cancer bone disease, demonstrating that knockdown of G6PD expression in prostate cancer cells resulted in a significant reduction in tumor burden within bone in vivo, associated with an increase in tumor cell apoptosis. Here, G6PD is linked to prostate cancer.